SNCG

SNCG (gamma-synuclein/persyn/BCSG1) is a small cytosolic synuclein-family protein with a dual biology: a developmentally regulated neuronal protein and an oncogenic factor aberrantly activated in epithelial cancers (PMID:9801372, PMID:9044857). In the nervous system it localizes to the cell bodies and axons of primary sensory, sympathetic, and motor neurons from the earliest stages of axonal outgrowth, a distribution distinct from the presynaptic CNS localization of other synucleins (PMID:9801372). SNCG was originally identified as a breast cancer-specific gene undetectable in normal breast but highly expressed in advanced infiltrating carcinoma, and tumor development correlates with overexpression of the wild-type protein rather than coding mutation (PMID:9044857, PMID:9700196). Its aberrant expression in malignancy is driven epigenetically through CpG island hypomethylation in exon 1 (PMID:16816827) and is transcriptionally suppressed by the growth-inhibitory cytokine oncostatin M (PMID:11016747). Functionally, SNCG acts as a pro-tumorigenic effector: gain-of-function stimulates anchorage-dependent and anchorage-independent growth (PMID:11016747), and in ovarian cancer it promotes proliferation, migration, invasion, and tumor formation in vitro and in vivo by activating PI3K/AKT signaling (PMID:32381034). The molecular partners and biochemical activity that underlie SNCG signaling have not been resolved in the available corpus.

1. 1997 Medium

   Established SNCG as a cancer-associated gene by linking its expression specifically to malignant rather than normal or benign breast tissue, raising the question of its role in tumor progression.

   Evidence Differential cDNA sequencing and in situ hybridization in breast tissue

   PMID:9044857

   Open questions at the time

   • Correlative expression only, no functional perturbation
   • Did not establish whether expression is cause or consequence of progression
2. 1998 Medium

   Defined SNCG as a cytosolic protein of peripheral neuron cell bodies and axons, distinguishing it from other presynaptic synucleins and establishing its baseline normal biology.

   Evidence Northern, in situ hybridization, Western, and immunohistochemistry across neuronal tissues

   PMID:9801372

   Open questions at the time

   • No functional perturbation of neuronal SNCG
   • Molecular role in axons not defined
3. 1998 Medium

   Resolved whether tumor association arises from mutation versus overexpression by mapping the gene and screening for coding changes, showing wild-type protein overexpression drives the tumor correlation.

   Evidence Genomic cloning, chromosomal localization, mutation screening, and antibody detection in aging cortex and breast tumors

   PMID:9700196

   Open questions at the time

   • Mechanism of overexpression not identified here
   • No causal test of overexpression in tumorigenesis
4. 2000 Medium

   Demonstrated that SNCG is both transcriptionally controllable and functionally pro-proliferative, moving it from a marker to a candidate driver.

   Evidence Transcription-rate measurement under oncostatin M, plus stable SNCG overexpression and growth assays in MCF-7 cells

   PMID:11016747

   Open questions at the time

   • Downstream effectors of pro-proliferative effect not defined
   • Single cell-line gain-of-function
5. 2006 Low

   Identified an epigenetic basis for aberrant SNCG expression, implicating CpG island hypomethylation in exon 1 in cancer-specific activation.

   Evidence RT-PCR and methylation-specific PCR of exon 1 CpG island in ovarian tumors

   PMID:16816827

   Open questions at the time

   • Correlative MSP without causal demethylation perturbation
   • Single method and single lab
6. 2020 Medium

   Connected SNCG overexpression to a defined signaling output, showing PI3K/AKT activation mediates its metastasis-promoting function.

   Evidence Loss- and gain-of-function with phospho-kinase array, Western blot, and in vitro/in vivo assays in ovarian cancer cells

   PMID:32381034

   Open questions at the time

   • Direct molecular partner coupling SNCG to PI3K/AKT not identified
   • Single lab

• The biochemical activity of SNCG and the direct binding partners that link it to PI3K/AKT activation remain unidentified.
• No defined molecular activity or substrate
• No structural model
• Mechanism connecting cytosolic SNCG to receptor/kinase signaling unknown